BNGO
Bionano Genomics, Inc.
Price Chart
Latest Quote
$1.18
+0.02 (+1.71%)
Current Price
| Previous Close | $1.16 |
| Open | $1.18 |
| Day High | $1.19 |
| Day Low | $1.16 |
| Volume | 38,533 |
Stock Information
| Shares Outstanding | 11.47M |
| Total Debt | $17.01M |
| Cash Equivalents | $14.40M |
| Revenue | $28.74M |
| Net Income | $-31.60M |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $13.54M |
| EPS (TTM) | $-4.46 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.81M |
| Sales | $28.74M |
| Income | $-31.60M |
| Book/sh | $3.32 |
| Cash/sh | $1.26 |
| Employees | 95 |
Financial Ratios
| Quick Ratio | 0.87 |
| Current Ratio | 1.84 |
| Debt/Eq | 45.41 |
Returns & Margins
| ROA | -28.60% |
| ROE | -73.78% |
| Gross Margin | 46.97% |
| Operating Margin | -118.09% |
| Profit Margin | -109.95% |
Ownership
| Insider Ownership | 7.41% |
| Institutional Ownership | 10.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.06 |
| P/S | 0.47 |
| P/B | 0.36 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $1.21 |
| SMA50 | $1.22 |
| SMA200 | $1.55 |
| RSI | 39.96 |
| ATR | 0.0543 |
| Shares Float | 10.30M |
| Short Float | 9.79% |
| Short Ratio | 6.48 |
| Rel Volume | 0.25 |
Performance History
| Week | -0.86% |
| Month | +0.84% |
| Quarter | +5.34% |
| 6 Months | -24.85% |
| YTD | -25.80% |
| Year | -63.81% |
| 3 Years | -99.74% |
| 5 Years | -99.97% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.18 | 38,533 |
| 2026-06-17 | $1.16 | 111,100 |
| 2026-06-16 | $1.15 | 126,800 |
| 2026-06-15 | $1.16 | 83,600 |
| 2026-06-12 | $1.16 | 149,400 |
| 2026-06-11 | $1.19 | 89,300 |
| 2026-06-10 | $1.16 | 91,300 |
| 2026-06-09 | $1.16 | 227,400 |
| 2026-06-08 | $1.17 | 172,100 |
| 2026-06-05 | $1.17 | 212,400 |
| 2026-06-04 | $1.26 | 130,900 |
| 2026-06-03 | $1.30 | 251,400 |
| 2026-06-02 | $1.26 | 150,600 |
| 2026-06-01 | $1.25 | 122,100 |
| 2026-05-29 | $1.24 | 183,500 |
| 2026-05-28 | $1.25 | 157,300 |
| 2026-05-27 | $1.23 | 178,500 |
| 2026-05-26 | $1.22 | 159,400 |
| 2026-05-22 | $1.24 | 218,000 |
| 2026-05-21 | $1.23 | 188,000 |
| 2026-05-20 | $1.24 | 105,100 |
| 2026-05-19 | $1.17 | 107,900 |
| 2026-05-18 | $1.16 | 160,000 |
About Bionano Genomics, Inc.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
đ° Latest News
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2026-06-08T16:00:05Z
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors
Zacks âĸ 2026-05-28T12:55:02Z
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
IPO-Edge.com âĸ 2026-05-20T20:51:00Z
Bionano Genomics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T12:30:00Z
Bionano Genomics Inc (BNGO) Q1 2026 Earnings Call Highlights: Record Flow Cell Sales and ...
GuruFocus.com âĸ 2026-05-14T05:02:19ZBionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-13T21:35:02Z
Transcript: Bionano Genomics Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T21:10:01Z
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-12T12:30:02Z
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Zacks âĸ 2026-05-07T12:50:20Z
Bionano Genomics Inc (BNGO) Q4 2025 Earnings Call Highlights: Navigating Challenges with ...
GuruFocus.com âĸ 2026-03-24T03:00:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $15,323,000 | $30,396,000 | $26,550,000 | $21,857,000 |
| Cost Of Revenue | $15,323,000 | $30,396,000 | $26,550,000 | $21,857,000 |
| Total Revenue | $28,508,000 | $30,776,000 | $36,116,000 | $27,802,000 |
| Operating Revenue | $28,508,000 | $30,776,000 | $36,116,000 | $27,802,000 |
| Expenses | ||||
| Interest Expense | $298,000 | $2,373,000 | $-2,999,000 | $298,000 |
| Total Expenses | $61,847,000 | $107,054,000 | $173,340,000 | $159,500,000 |
| Other Income Expense | $2,414,000 | $-31,797,000 | $-78,169,000 | $-223,000 |
| Other Non Operating Income Expenses | $2,414,000 | $-716,000 | $-148,000 | $-223,000 |
| Net Non Operating Interest Income Expense | $4,597,000 | $-3,909,000 | $-17,038,000 | $1,209,000 |
| Interest Expense Non Operating | $298,000 | $2,373,000 | $-2,999,000 | $298,000 |
| Operating Expense | $46,524,000 | $76,658,000 | $146,790,000 | $137,643,000 |
| Total Other Finance Cost | - | $3,637,000 | $23,348,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Net Interest Income | $4,597,000 | $-3,909,000 | $-17,038,000 | $1,209,000 |
| Interest Income | $4,895,000 | $2,101,000 | $3,311,000 | $1,507,000 |
| Normalized Income | $-26,395,000 | $-87,463,010 | $-170,856,410 | $-132,596,000 |
| Net Income From Continuing And Discontinued Operation | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Total Operating Income As Reported | $-33,339,000 | $-103,983,000 | $-215,245,000 | $-131,698,000 |
| Net Income Common Stockholders | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Net Income | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Net Income Including Noncontrolling Interests | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Net Income Continuous Operations | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Pretax Income | $-26,328,000 | $-111,984,000 | $-232,431,000 | $-130,712,000 |
| Special Income Charges | $0 | $-31,081,000 | $-78,021,000 | $0 |
| Interest Income Non Operating | $4,895,000 | $2,101,000 | $3,311,000 | $1,507,000 |
| Operating Income | $-33,339,000 | $-76,278,000 | $-137,224,000 | $-131,698,000 |
| Gross Profit | $13,185,000 | $380,000 | $9,566,000 | $5,945,000 |
| Per Share | ||||
| Diluted EPS | $-2.46 | $-60.05 | $-408.60 | $-267.71 |
| Basic EPS | $-2.46 | $-60.05 | $-408.60 | $-267.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-6,527,010 | $-16,384,410 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,299,000 | $-64,304,000 | $-143,497,000 | $-120,574,000 |
| Total Unusual Items | $0 | $-31,081,000 | $-78,021,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-31,081,000 | $-78,021,000 | $0 |
| Reconciled Depreciation | $9,731,000 | $14,226,000 | $13,912,000 | $9,840,000 |
| EBITDA (Bullshit earnings) | $-16,299,000 | $-95,385,000 | $-221,518,000 | $-120,574,000 |
| EBIT | $-26,030,000 | $-109,611,000 | $-235,430,000 | $-130,414,000 |
| Diluted Average Shares | $10,740,200 | $1,865,400 | $568,999 | $495,304 |
| Basic Average Shares | $10,740,200 | $1,865,400 | $568,999 | $495,304 |
| Diluted NI Availto Com Stockholders | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Tax Provision | $67,000 | $33,000 | $62,000 | $1,884,000 |
| Impairment Of Capital Assets | $0 | $19,683,000 | $77,280,000 | $0 |
| Restructuring And Mergern Acquisition | $0 | $8,022,000 | $741,000 | - |
| Research And Development | $11,374,000 | $24,803,000 | $54,032,000 | $49,047,000 |
| Selling General And Administration | $35,150,000 | $51,855,000 | $92,758,000 | $88,596,000 |
| Other Special Charges | - | $3,376,000 | - | - |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $40,079,000 | $25,670,000 | $62,185,000 | $130,968,000 |
| Total Assets | $73,584,000 | $76,670,000 | $214,404,000 | $307,502,000 |
| Total Non Current Assets | $28,198,000 | $37,181,000 | $74,284,000 | $150,202,000 |
| Other Non Current Assets | $2,694,000 | $3,154,000 | $7,831,000 | $2,814,000 |
| Goodwill And Other Intangible Assets | $4,345,000 | $9,705,000 | $33,972,000 | $118,430,000 |
| Other Intangible Assets | $4,345,000 | $9,705,000 | $33,972,000 | $41,141,000 |
| Current Assets | $45,386,000 | $39,489,000 | $140,118,000 | $157,298,000 |
| Other Current Assets | $1,759,000 | $1,318,000 | $976,000 | $2,412,000 |
| Restricted Cash | $10,266,000 | $11,000,000 | $35,117,000 | - |
| Prepaid Assets | $3,432,000 | $1,801,000 | $4,701,000 | $4,443,000 |
| Inventory | $5,448,000 | $11,121,000 | $22,892,000 | $29,761,000 |
| Receivables | $5,212,000 | $4,774,000 | $9,661,000 | $7,496,000 |
| Accrued Interest Receivable | $12,000 | $22,000 | $342,000 | $474,000 |
| Accounts Receivable | $5,200,000 | $4,752,000 | $9,319,000 | $7,022,000 |
| Allowance For Doubtful Accounts Receivable | $-18,000 | $-157,000 | $-483,000 | $-293,000 |
| Gross Accounts Receivable | $5,218,000 | $4,909,000 | $9,802,000 | $7,315,000 |
| Cash Cash Equivalents And Short Term Investments | $19,269,000 | $9,475,000 | $66,771,000 | $113,186,000 |
| Cash And Cash Equivalents | $2,990,000 | $9,173,000 | $17,948,000 | $5,091,000 |
| Debt | ||||
| Total Debt | $6,915,000 | $6,935,000 | $9,610,000 | $11,668,000 |
| Long Term Debt And Capital Lease Obligation | $5,969,000 | $3,684,000 | $7,175,000 | $9,123,000 |
| Current Debt And Capital Lease Obligation | $946,000 | $3,251,000 | $2,435,000 | $2,545,000 |
| Net Debt | - | - | $51,855,000 | - |
| Current Debt | - | - | $69,803,000 | - |
| Other Current Borrowings | - | - | $69,803,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $29,160,000 | $41,295,000 | $118,247,000 | $58,104,000 |
| Total Non Current Liabilities Net Minority Interest | $6,218,000 | $3,951,000 | $18,219,000 | $22,220,000 |
| Non Current Deferred Liabilities | $249,000 | $267,000 | $154,000 | $127,000 |
| Current Liabilities | $22,942,000 | $37,344,000 | $100,028,000 | $35,884,000 |
| Other Current Liabilities | $9,979,000 | $20,362,000 | $78,337,000 | $9,382,000 |
| Current Deferred Liabilities | $967,000 | $1,145,000 | $800,000 | $888,000 |
| Payables And Accrued Expenses | $6,952,000 | $10,327,000 | $13,035,000 | $16,067,000 |
| Payables | $5,862,000 | $7,691,000 | $11,483,000 | $13,359,000 |
| Total Tax Payable | $272,000 | $729,000 | $1,099,000 | $825,000 |
| Accounts Payable | $5,590,000 | $6,962,000 | $10,384,000 | $12,534,000 |
| Other Non Current Liabilities | - | - | $10,890,000 | $12,970,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $44,424,000 | $35,375,000 | $96,157,000 | $249,398,000 |
| Total Equity Gross Minority Interest | $44,424,000 | $35,375,000 | $96,157,000 | $249,398,000 |
| Stockholders Equity | $44,424,000 | $35,375,000 | $96,157,000 | $249,398,000 |
| Gains Losses Not Affecting Retained Earnings | $17,000 | $27,000 | $23,000 | $-1,124,000 |
| Other Equity Adjustments | $17,000 | $27,000 | $23,000 | $-1,124,000 |
| Retained Earnings | $-719,620,000 | $-693,225,000 | $-581,208,000 | $-348,715,000 |
| Other | ||||
| Ordinary Shares Number | $10,740,200 | $1,865,400 | $762,533 | $495,304 |
| Share Issued | $10,740,200 | $1,865,400 | $762,533 | $495,304 |
| Tangible Book Value | $40,079,000 | $25,670,000 | $62,185,000 | $130,968,000 |
| Invested Capital | $44,424,000 | $35,375,000 | $96,157,000 | $249,398,000 |
| Working Capital | $22,444,000 | $2,145,000 | $40,090,000 | $121,414,000 |
| Capital Lease Obligations | $6,915,000 | $6,935,000 | $9,610,000 | $11,668,000 |
| Total Capitalization | $44,424,000 | $35,375,000 | $96,157,000 | $249,398,000 |
| Additional Paid In Capital | $764,026,000 | $728,573,000 | $677,342,000 | $599,234,000 |
| Capital Stock | $1,000 | $0 | $0 | $3,000 |
| Common Stock | $1,000 | $0 | $0 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $249,000 | $267,000 | $154,000 | $127,000 |
| Long Term Capital Lease Obligation | $5,969,000 | $3,684,000 | $7,175,000 | $9,123,000 |
| Current Deferred Revenue | $967,000 | $1,145,000 | $800,000 | $888,000 |
| Current Capital Lease Obligation | $946,000 | $3,251,000 | $2,435,000 | $2,545,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,537,000 | $1,983,000 | $5,030,000 | $7,002,000 |
| Current Provisions | $561,000 | $276,000 | $391,000 | - |
| Current Accrued Expenses | $1,090,000 | $2,636,000 | $1,552,000 | $2,708,000 |
| Net PPE | $21,159,000 | $24,322,000 | $32,481,000 | $28,958,000 |
| Accumulated Depreciation | $-28,200,000 | $-26,862,000 | $-19,077,000 | $-13,077,000 |
| Gross PPE | $49,359,000 | $51,184,000 | $51,558,000 | $42,035,000 |
| Leases | $2,886,000 | $3,325,000 | $3,746,000 | $4,001,000 |
| Other Properties | $43,766,000 | $45,136,000 | $44,828,000 | $36,412,000 |
| Machinery Furniture Equipment | $2,707,000 | $2,723,000 | $2,984,000 | $1,622,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $16,279,000 | $302,000 | $48,823,000 | $108,095,000 |
| Treasury Shares Number | - | - | $0 | - |
| Goodwill | - | - | $0 | $77,289,000 |
| Finished Goods | - | - | - | $17,387,000 |
| Work In Process | - | - | - | $7,055,000 |
| Raw Materials | - | - | - | $5,319,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,345,000 | $-69,025,000 | $-126,872,000 | $-128,118,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-16,345,000 | $-68,922,000 | $-125,181,000 | $-124,816,000 |
| Cash Flow From Continuing Operating Activities | $-16,345,000 | $-68,922,000 | $-125,181,000 | $-124,816,000 |
| Operating Gains Losses | $962,000 | $6,448,000 | $405,000 | $270,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-12,747,000 | $73,839,000 | $24,158,000 | $82,767,000 |
| Cash Flow From Continuing Investing Activities | $-12,747,000 | $73,839,000 | $24,158,000 | $82,767,000 |
| Capital Expenditure | - | $-103,000 | $-1,691,000 | $-3,302,000 |
| Net Other Investing Changes | - | - | - | $694,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $31,098,000 | $44,433,000 | $57,697,000 | $23,128,000 |
| Financing Cash Flow | $24,039,000 | $-13,685,000 | $113,815,000 | $23,007,000 |
| Cash Flow From Continuing Financing Activities | $24,039,000 | $-13,685,000 | $113,815,000 | $23,007,000 |
| Net Other Financing Charges | $-2,122,000 | $-10,075,000 | $-14,965,000 | $-578,000 |
| Net Common Stock Issuance | $31,098,000 | $44,433,000 | $57,697,000 | $23,128,000 |
| Common Stock Issuance | $31,098,000 | $44,433,000 | $57,697,000 | $23,128,000 |
| Other | ||||
| Repayment Of Debt | $-4,946,000 | $-66,058,000 | $-9,047,000 | $-36,000 |
| Issuance Of Debt | $0 | $18,000,000 | $80,000,000 | $0 |
| Interest Paid Supplemental Data | $1,674,000 | $10,653,000 | $1,648,000 | $298,000 |
| End Cash Position | $4,509,000 | $9,573,000 | $18,348,000 | $5,491,000 |
| Beginning Cash Position | $9,573,000 | $18,348,000 | $5,491,000 | $24,571,000 |
| Effect Of Exchange Rate Changes | $-11,000 | $-7,000 | $65,000 | $-38,000 |
| Changes In Cash | $-5,053,000 | $-8,768,000 | $12,792,000 | $-19,042,000 |
| Proceeds From Stock Option Exercised | $9,000 | $15,000 | $130,000 | $493,000 |
| Net Issuance Payments Of Debt | $-4,946,000 | $-48,058,000 | $70,953,000 | $-36,000 |
| Net Long Term Debt Issuance | $-4,946,000 | $-48,058,000 | $70,953,000 | $-36,000 |
| Long Term Debt Payments | $-4,946,000 | $-66,058,000 | $-9,047,000 | $-36,000 |
| Long Term Debt Issuance | $0 | $18,000,000 | $80,000,000 | $0 |
| Net Investment Purchase And Sale | $-12,747,000 | $73,942,000 | $25,753,000 | $116,693,000 |
| Sale Of Investment | $229,132,000 | $306,963,000 | $137,017,000 | $200,888,000 |
| Purchase Of Investment | $-241,879,000 | $-233,021,000 | $-111,264,000 | $-84,195,000 |
| Net PPE Purchase And Sale | $0 | $-103,000 | $-1,691,000 | $-3,174,000 |
| Purchase Of PPE | $0 | $-103,000 | $-1,691,000 | $-3,200,000 |
| Change In Working Capital | $514,000 | $4,157,000 | $-14,770,000 | $-27,939,000 |
| Change In Other Current Assets | $60,000 | $4,678,000 | $-5,020,000 | $-1,130,000 |
| Change In Payables And Accrued Expense | $-1,952,000 | $-5,656,000 | $-4,517,000 | $2,315,000 |
| Change In Accrued Expense | $-580,000 | $-2,236,000 | $-2,522,000 | $366,000 |
| Change In Payable | $-1,372,000 | $-3,420,000 | $-1,995,000 | $1,949,000 |
| Change In Account Payable | $-1,372,000 | $-3,420,000 | $-1,995,000 | $1,949,000 |
| Change In Prepaid Assets | $-2,062,000 | $1,583,000 | $1,213,000 | $-3,197,000 |
| Change In Inventory | $4,916,000 | $-587,000 | $-4,150,000 | $-23,676,000 |
| Change In Receivables | $-448,000 | $4,139,000 | $-2,296,000 | $-2,251,000 |
| Changes In Account Receivables | $-448,000 | $4,139,000 | $-2,296,000 | $-2,251,000 |
| Other Non Cash Items | $443,000 | $-8,951,000 | $16,421,000 | $794,000 |
| Stock Based Compensation | $4,534,000 | $9,736,000 | $15,178,000 | $22,417,000 |
| Unrealized Gain Loss On Investment Securities | $-5,158,000 | $-8,118,000 | $-575,000 | - |
| Asset Impairment Charge | $0 | $26,913,000 | $77,280,000 | $0 |
| Amortization Of Securities | $-976,000 | $-1,316,000 | $-539,000 | $638,000 |
| Depreciation Amortization Depletion | $9,731,000 | $14,226,000 | $13,912,000 | $9,840,000 |
| Depreciation And Amortization | $9,731,000 | $14,226,000 | $13,912,000 | $9,840,000 |
| Depreciation | $9,731,000 | $14,226,000 | $13,912,000 | $9,840,000 |
| Gain Loss On Sale Of PPE | $962,000 | $3,058,000 | $382,000 | $204,000 |
| Net Income From Continuing Operations | $-26,395,000 | $-112,017,000 | $-232,493,000 | $-132,596,000 |
| Net Business Purchase And Sale | - | $0 | $96,000 | $-31,344,000 |
| Sale Of Business | - | $0 | $96,000 | $0 |
| Gain Loss On Investment Securities | - | $14,000 | $23,000 | $66,000 |
| Purchase Of Business | - | - | $0 | $-31,344,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-102,000 |
| Purchase Of Intangibles | - | - | $0 | $-102,000 |
| Sale Of PPE | - | - | $0 | $26,000 |
| Deferred Tax | - | - | $0 | $1,760,000 |
| Deferred Income Tax | - | - | $0 | $1,760,000 |
| Interest Paid Cfo | - | - | - | $0 |
| Provisionand Write Offof Assets | - | - | - | $649,000 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-16